In February 2025, the Medicines and Healthcare products Regulatory Agency (MHRA) published an updated Drug Safety Update. This states that the requirement for a review by two specialists remains in place for patients initiating valproate under 55 years of age, but the Commission on Human Medicines have advised that it will not be required for men (or males) currently taking valproate.
The MHRA have produced three infographics to clarify in which situations review by two specialists may be required:
- for female patients under 55 years old
- for male patients under 55 years old
- for male and female patients 55 years and older
A list of who might qualify as a specialist can be found at valproate safety measures.